
    
      It is designed as a multicenter, randomized, double-blind, double-simulation, high and low
      dose group, active comparator-controlled, parallel-group study to investigate the efficacy
      and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux
      esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.
    
  